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ABSTRACT
Transcribed ultraconserved regions (T-UCRs) are a class of non-coding RNAs with 
100% sequence conservation among human, rat and mouse genomes. T-UCRs are 
differentially expressed in several cancers, however their expression in pancreatic 
adenocarcinoma (PDAC) has not been studied. We used a qPCR array to profile all 
481 T-UCRs in pancreatic cancer specimens, pancreatic cancer cell lines, during 
experimental pancreatic desmoplasia and in the pancreases of P48Cre/wt; KrasLSL-G12D/wt 
mice. Fourteen, 57 and 29% of the detectable T-UCRs were differentially expressed in 
the cell lines, human tumors and transgenic mouse pancreases, respectively. The vast 
majority of the differentially expressed T-UCRs had increased expression in the cancer. 
T-UCRs were monitored using an in vitro model of the desmoplastic reaction. Twenty-
five % of the expressed T-UCRs were increased in the HPDE cells cultured on PANC-1 
cellular matrix. UC.190, UC.233 and UC.270 were increased in all three human data sets. 
siRNA knockdown of each of these three T-UCRs reduced the proliferation of MIA PaCa-
2 cells up to 60%. The expression pattern among many T-UCRs in the human and mouse 
pancreases closely correlated with one another, suggesting that groups of T-UCRs are 
co-activated in PDAC. Successful knockout of the transcription factor EGR1 in PANC-1 
cells caused a reduction in the expression of a subset of T-UCRs suggesting that EGR1 
may control T-UCR expression in PDAC. We report a global increase in expression of 
T-UCRs in both human and mouse PDAC. Commonalties in their expression pattern 
suggest a similar mechanism of transcriptional upregulation for T-UCRs in PDAC.
INTRODUCTION
Pancreatic cancer is the fourth leading cause of 
cancer-related death in the USA [1]. Invasive pancreatic 
ductal adenocarcinoma (PDAC) accounts for more 
than 85% of all pancreatic tumors. PDAC has a 5 year 
survival rate of 7% [1] due to early dissemination and 
the rapid and insidious nature of growth and is predicted 
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to be the second most lethal cancer in the USA by 2030 
[2].
Like most cancers, PDAC arises from genetic 
alterations that are compounded by epigenetic mechanisms 
such as histone modifications and DNA methylation [3]. 
Whole genomic sequence analysis of 24 PDACs revealed 
that the four most frequently mutated genes were KRAS, 
p53, CDKN2A (p16) and SMAD4 [4]. KRAS was mutated 
in greater than 90% of the cases [4]. These findings were 
confirmed in the whole genome sequencing of pairs of 
PDAC and adjacent benign tissue from 3 patients and 
RNAseq from 2 tumors [5]. Both studies [4, 5] focused 
primarily on coding genes and transcripts.
It is widely accepted that non-coding RNAs play 
an important role in normal development, physiological 
homeostasis and disease [6]. Knowledge stemming from 
differential microRNA (miRNA) expression studies 
of PDAC [7–9] has been used to develop potential 
diagnostic [10, 11] and therapeutic applications [12, 
13]. miRNA represents one of many classes of non-
coding RNA that may play a role in the development, 
progression or metastasis of PDAC. Conceivably, other 
non-coding RNAs such as large intergenic non-coding 
RNAs (lncRNAs) [14], small nucleolar RNAs (snoRNAs), 
PIWI-interacting RNAs (piRNAs) and the transcribed-
ultraconserved regions (T-UCRs) may also contribute to 
PDAC tumorigenesis.
T-UCRs are a set of 481 sequences that are strictly 
conserved among orthologous regions of the human, rat 
and mouse genome [15]. Nearly all of these gene segments 
are conserved in the chicken and dog genomes, with an 
average of 95 and 99% identity, respectively. They are 
at least 200 bp in length and are located in intergenic 
regions or within introns or exons of coding genes. The 
precise function of the T-UCRs is largely unknown. The 
T-UCR UC.283+A was shown to decrease pri-miR-195 
biogenesis by impairing microprocessor recognition and 
pri-miRNA cropping [16]. We previously reported that 
many (~90%) of the T-UCRs are expressed in human 
cells and that T-UCR expression varied in a set of human 
leukemias and colorectal cancer specimens from patients 
[17]. Furthermore, the location of the T-UCRs was found 
in cancer associated genomic regions [17]. It has also been 
reported that single nucleotide polymorphisms (SNPs) and 
genetic alterations in UCRs may be associated with higher 
risk for familial breast cancer and colorectal carcinoma 
[18–20]. T-UCRs are differentially expressed in leukemias, 
hepatocellular carcinoma, neuroblastoma, prostate cancer 
and Barrett’s esophagus [21–25]. To our knowledge, the 
expression of T-UCRs in PDAC has not been reported.
We used a qPCR low density array to profile the 
481 T-UCRs in PDAC patient specimens and cell lines 
and in the pancreas of genetically engineered mice. We 
found that a large number of T-UCRs were transcribed 
in pancreas tissue and that a majority of these increase 
with disease progression. Several T-UCRs possessed 
oncogenic properties related to proliferation. Moreover, 
many T-UCRs were expressed similarly across different 
tissues suggesting that they share a common means of 
transcriptional and/or post-transcriptional regulation.
RESULTS
Increased T-UCR expression in PDAC tissues, 
cell lines and during experimental desmoplasia
The expression of 481 T-UCRs was profiled in a 
discovery cohort of 20 pancreas specimens (4 normal, 
8 adjacent benign and 8 PDAC). Of the 307 expressed 
T-UCRs in the human pancreas tissues, 175 (57%) 
were differentially expressed in the PDAC compared to 
normal and benign pancreas. All 175 of the differentially 
expressed T-UCRs were increased in the cancer and none 
were decreased (Figure 1A, Supplementary Table S1). 
The expression of many T-UCRs sequentially increased 
from normal to adjacent benign to PDAC. Representative 
examples are shown in Supplementary Figure S1A-S1C.
The T-UCR expression in old P48Cre/wt;KrasLSL-G12D/wt 
mice were compared to that of control mice. Similar to the 
PDAC patient specimens, a large proportion of the 328 
detectable T-UCRs increased in the old P48Cre/wt;KrasLSL-
G12D/wt versus control mice (95 T-UCRs were increased and 
2 were decreased, Figure 1B, Supplementary Table S2). A 
trend of increasing T-UCR expression among the control, 
young and old P48Cre/wt;KrasLSL-G12D/wt mice was generally 
observed. T-UCR expression in the mice mosaic for 
KrasG12D expression, Pdx-1-Cre; KrasLSL-G12D/wt, typically 
fell in between that of the old and young p48Cre/wt;KrasLSL-
G12D/wt mice (Supplementary Figure S1D-S1F). This finding 
is not surprising due to the mosaic nature of KrasG12D 
expression in the Pdx-1-Cre; KrasLS-LG12D/wt compared to 
p48Cre/wt;KrasLSL-G12D/+ mice.
Comparing the T-UCR expression in the 4 PDAC 
cell lines to 2 normal pancreas cells showed a pattern 
of differential expression, though not as pronounced 
as in the tissues. Of the 307 detectable T-UCRs in the 
cell lines, 42 were differentially expressed (13.7%); 38 
increased (90.5%) and 4 decreased (9.5%) (Figure 1C, 
Supplementary Table S3).
PDAC is frequently associated with an intense area 
of fibrosis known as the desmoplastic reaction composed 
of bands of fibrous stroma, collagen I and collagen II 
surrounding the malignant cells. The desmoplastic reaction 
may be studied experimentally by culturing cells on an 
extracellular matrix previously deposited by another cell 
[26]. To determine if the T-UCR expression is increased 
or decreased during desmoplasia, HPDE cells were 
cultured on a PANC-1 extracellular matrix. The T-UCR 
expression in HPDE cells cultured on the PANC-1 matrix 
was compared to that of HPDE cells cultured on plastic. 
Of the 383 expressed T-UCRs, 96 increased (25%) when 
HPDE cells were cultured on the PANC-1 matrix (> 1.5-
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fold, P < 0.05) while two (0.52%) had reduced expression 
(Figure 1D, Supplementary Table S4).
We next compared the genomic location of the 
T-UCRs that are increased in the mouse and human 
tissue data sets using the annotation as described by 
Mestdagh, et al., [27]. Specifically, we compared the 
T-UCRs that are increased in the PDAC compared to 
normal and benign tissue and in the pancreas of old 
versus control mice. Most of the increased T-UCRs are 
located in the intragenic regions (i.e. intronic, exonic and 
partly exonic) (Figure 1E, 1F). Over half of the increased 
T-UCRs in both comparisons were intronic T-UCRs 
Figure 1: Differential T-UCR expression in PDAC tissues, cell lines and during experimental desmoplasia. The T-UCR 
expression was determined by qPCR in A. normal, adjacent benign and PDAC tissues from patients, B. in the pancreas of control and 
P48cre/wt; KrasLSL-G12D/wt (median 239 day old) transgenic mice, C. in PDAC and normal pancreas cell lines and D. during experimental 
desmoplasia. Expression values were converted to Log2 (fold change) and the Log2 (fold change) are compared to p-values using Volcano 
plots. Dots represent mean independent biological replicates for a given T-UCR. A threshold of P < 0.05 and fold change greater than 1.5-
fold (red symbols) was applied to determine statistical significance. The genomic location of T-UCRs with increased expression in the 
PDAC compared to normal pancreas in human E. and in the pancreases of the old versus control transgenic mice F.
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while only 7 and 12% in the human and mouse data sets, 
respectively, were intergenic T-UCRs (Figure 1E, 1F). It 
is significant that such a large percentage of the T-UCRs 
with increased expression are intragenic as 39% of the 
481 T-UCRs are classified as intergenic. In summary, 
the vast majority of the genes encoding T-UCRs that are 
increased in the mouse and human tissue data sets reside 
in intragenic rather than intergenic regions.
A comparison of all differentially expressed 
(increased) T-UCRs evaluated in the human cells/tissues 
showed that three T-UCRs (UC.190, UC.233 and UC.270) 
were increased in each of the data sets (Figure 2A). Shown 
in Figure 2 is the expression of UC.190, UC.233 and 
UC.270 in the PDAC tissues compared to normal and 
adjacent benign pancreas from the discovery cohort. We 
then determined the expression of these three T-UCRs 
in a validation cohort of 4 normal pancreas, 13 adjacent 
benign pancreas and 19 PDAC. The fold-change in 
expression of UC.190, UC.233 and UC.270 in the PDAC 
compared to the normal and benign pancreas was >1.5-
fold. The p values for the UC.190, UC.233 and UC.270 
comparisons (Tumor versus Normal and Benign) in the 
validation cohort were 0.173, < 0.05, 0.0562, respectively. 
The expression of UC.190, UC.233 and UC.270 in the 
validation cohort is presented in Figure 2. Comparing the 
UC.190, UC.233 and UC.270 expression in the control 
and old P48Cre/wt; KrasLSL-G12D/wt mice showed that the 
expression of all three T-UCRs were increased in the old 
P48Cre/wt; KrasLSL-G12D/wt versus control mice (Fold change 
> 1.5) however the p-value for UC.270 was not significant 
(Supplementary Figure S2).
UC.190, UC.233 and UC.270 are required for 
sustained proliferation of pancreatic cancer cells
To explore the biological function of the T-UCRs, 
we next used the RNA knockdown approach. The three 
T-UCRs with increased expression (UC.190, UC.233 
and UC.270, Figure 2) were selected for knockdown. 
The specific strand that UC.190, UC.233 and UC.270 are 
expressed from was determined by strand specific qPCR 
(data not shown). The results showed the following strand 
specific expression: UC.190 (plus strand), UC.233 (plus 
strand) and UC.270 (minus strand). For each T-UCR 
(UC.190, UC.233 and UC.270) we designed three distinct 
siRNAs targeting different expressed segments of the 
T-UCRs or one segment for the gapmers. The effect of 
the knockdown on T-UCR expression, T-UCR host gene 
expression and cell proliferation was evaluated. T-UCR 
expression was reduced by 60% or greater for all three 
siRNAs (Supplementary Figure S3A). T-UCR host gene 
expression was also reduced by the siRNA (Supplementary 
Figure S3B). Cell proliferation was measured following 
siRNA treatment at two different time points (72 h and 
96 h) with the most significant reduction in viability 
occurring at 96 h. The mean reduction of all three siRNAs 
in MIA PaCa-2 cell proliferation following 96 h of siRNA 
exposure was 34%, 51% and 44% for the UC.190, UC.233 
and UC.270, respectively (Figure 3). To further explore 
the effects of gene knockdown on cell proliferation 
we employed the gapmer oligo knockdown method. 
Gapmers to each T-UCR reduced cell proliferation from 
30% to greater than 80% (Supplementary Figure S3C, 
S3E). Gapmers reduced the expression of each T-UCR 
up to 80% and reduced host gene expression up to 90% 
(Supplmentary Figure S3D, S3F).
Strong correlation of T-UCR expression in 
tissues
In neuroblastoma, specific T-UCRs displayed 
strong correlations in their expression [27], therefore, we 
wanted to look for similar trends of T-UCR expression in 
pancreatic cancer. The expression pattern among many 
T-UCRs in the mouse or patient tissues closely correlated 
with one another. This was to be expected for T-UCRs 
directly adjacent to one another in the genome that are 
likely transcribed as a unit such as human UC.418 and 
UC.419 (Figure 4A) or mouse UC.263 and UC.264 
(Figure 4C). Interestingly, we found strong correlations 
in the expression of T-UCRs that are located on different 
chromosomes. For example, UC.26 and UC.116 (Figure 
4B) in human and UC.285 and UC.418 (Figure 4D) in 
mouse. The pairwise Pearson correlation coefficients 
for all 307 and 328 expressed T-UCRs in the patient 
specimens and mouse pancreases, respectively, were 
determined and presented as heatmaps. The large portions 
of red color in each heatmap indicates a strong degree of 
expression correlation in both the human (Figure 4E) and 
mouse (Figure 4F) data. High resolution images of Figure 
4E and 4F may be found as Supplementary Figure S4A 
and S4B, respectively.
Transcriptional regulation of increased T-UCR 
expression
The large increase in expression of many of the 
T-UCRs in pancreatic cancer suggests common means 
of regulation for these non-coding transcripts in the 
disease. Universal mechanism(s) for up-regulation for 
these T-UCRs would account for the global increase and 
correlation in expression between T-UCRs that reside in 
different chromosomes (Figure 4B, 4D). One possibility 
for the strong correlation among T-UCRs is that they are 
under control of similar transcription factors. To further 
investigate this, we identified transcription factors in 
human cancer cell lines by Encode RNA ChipSeq that bind 
to the putative promoter regions of the intronic and exonic 
T-UCR host genes. Up to 20 kbp of sequence upstream 
of the putative transcription start site for the intronic and 
exonic T-UCR host genes were examined. Intergenic 
T-UCRs were not evaluated since their promoters cannot 
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Figure 2: Expression of UC.190, UC.233 and UC.270 in discovery and validation cohorts of patients. The T-UCR expression 
was determined by qPCR in PDAC tissue specimens, cell lines and during experimental desmoplasia. A. Overlap was determined in those 
T-UCRs with increased expression in each setting. Three T-UCRs (UC.190, UC.233 and UC.270) were increased in all three data sets. The 
expression of UC.190 B, C., UC.233 D, E. and UC.270 F, G. in normal pancreas, adjacent benign tissue and PDAC was determined by 
qPCR in discovery (B, D, F) and validation (C, E, G) cohorts of patient tissues. * P < 0.05; ** P < 0.01; *** P < 0.001.
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be easily predicted. Of the 181 intronic and exonic T-UCRs 
examined, we identified several transcription factors that 
might be involved in transcribing these T-UCRs. To find 
the most informative transcriptional factors for functional 
studies, we compared the expression of these 17 putative 
transcription factors to our gene expression profiling data of 
human pancreas and PDAC (GSE71989). The expression of 
EGR1 (a transcriptional regulator that belongs to the family 
of C2H2-type zinc-finger proteins.) was highly increased 
in PDAC (Figure 5A) and had the lowest p-value and 
highest fold change in expression of the 17 transcription 
factors studied (Figure 5B, Supplementary Table S5). To 
functionally evaluate the role that EGR1 has on T-UCR 
expression in PDAC, EGR1 was successfully knocked out 
in the PANC-1 cells using the CRISPR/Cas 9 technology 
(Figure 5C). The expression of the 481 T-UCRs was 
profiled in both wild type and EGR1 knockout PANC-
1 cells. The expression of 28 T-UCRs was reduced in the 
knockout cells (Fold change < 1.5, P < 0.05) compared to 
only 7 T-UCRs that were increased with EGR1 knockout 
(Figure 5D). These data suggests that EGR1 plays a role 
in regulating the transcription of a subset of the T-UCRs in 
pancreatic cancer.
DISCUSSION
Differential expression of the T-UCR class of non-
coding RNAs has been previously established in human 
cancer [17, 21–25]. We report that a large number of 
T-UCRs are differentially expressed in PDAC. The 
expression is predominately increased in human PDAC 
tissues and cell lines and in mouse models containing an 
activating Kras mutation. We identified three T-UCRs 
(UC.190, UC.233, UC.270) that were increased in all 
human models studied. siRNA or gapmer knockdown of 
these T-UCRs decreased cell viability, suggesting they 
might play a role in tumor promotion. T-UCRs themselves 
have been shown to have roles as gene enhancers in the 
mouse and bind miRNA in human cell lines [16, 17, 28]. 
It is conceivable, therefore, that T-UCRs play a regulatory 
role in promoting PDAC tumorigenesis by inducing 
oncogenes and/or down-regulating tumor suppressors.
The general pattern of T-UCR up-regulation in the 
different models of PDAC studied here is particularly 
striking. Of the many T-UCR expression profiling studies 
of human cancer to date [17, 21–23, 27, 29, 30], no similar 
trend of global T-UCR up regulation in solid tumors or 
Figure 3: Effect of T-UCR knockdown on MIA PaCa-2 cells proliferation. MIA PaCa-2 cells were exposed to 40 nM of control 
siRNA (black bars) or siRNA to UC.190, UC.233 or UC.270 for 96 h. Three different siRNAs - siRNA_1 (red), siRNA_2 (green) and 
siRNA_3 (blue) were evaluated for each T-UCR. The effect of the siRNA knockdown of T-UCRs on cell proliferation was compared to 
control siRNA. * P < 0.05; **P < 0.01. Representative data from duplicate experiments.
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Figure 4: T-UCR have similar pattern of expression in both human and mouse tissues. Correlations were determined for 
T-UCR expression in human A, B. and mouse C, D. tissues that are directly adjacent to one another (A, C) or on different chromosomes 
(B, D). The Pearson correlations were determined for all T-UCR gene expression in both human and mouse tissues. Of the 481 T-UCRs 
profiled by qPCR in 24 specimens of PDAC, adjacent benign and normal pancreas tissues, 307 were independently expressed. The pairwise 
Pearson correlation coefficients for all 307 expressed T-UCRs in these specimens were determined E. Of the 481 T-UCRs profiled by 
qPCR in pancreas of young and old P48Cre/wt; KrasLSL-G12D/wt, Pdx-1-Cre; KrasLSL-G12D/wt and control mice, 328 were independently expressed. 
The pairwise Pearson correlation coefficients for all 328 expressed T-UCRs in these specimens were determined F. Data are presented as 
heatmaps with red having the highest correlation and blue the lowest.
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leukemia/lymphoma exists. Of note, the expression of 
many T-UCRs, including those that reside on different 
chromosomes, correlated with one another in pancreatic 
tissues (Figure 4). This suggests a universal mechanism 
of T-UCR regulation in pancreatic cancer, perhaps 
through regulation by similar transcription factors. 
DNA hypermethylation resulted in T-UCR silencing in a 
variety of cancer cell lines and patient tumor specimens 
[31]. Since this study did not evaluate pancreatic cells or 
tissues, it is possible that the T-UCR upregulation may be 
unique to PDAC.
EGR1 was one transcription factor that we 
hypothesized could be responsible for regulating the 
T-UCR expression in PDAC (Figure 5). ChIP-Seq 
demonstrated that EGR1 globally increases miRNA 
expression in K562 cells stimulated with PMA [32]. 
EGR1 was increased in the patient data set (Figure 5A). 
EGR1 has been shown to be a stress response gene 
with increased expression in pancreatic acini following 
exposure to caerulein, an inducer of pancreatitis [33, 34]. 
The limitations of our experiment include transcription 
factor knockout in a cancer cell line and not in an 
organism. To definitely demonstrate EGR1 regulation 
of a subset of T-UCRs, the experiment would need to be 
repeated in an EGR1 knockout mice, preferably a pancreas 
specific conditional knockout. Since only a subset of 
T-UCRs were differentially expressed following EGR1 
knockdown, other transcriptional or epigenetic regulation 
is likely. Mestdagh, et al., observed an association between 
H3K4me3 (a mark of active transcription) and the T-UCRs 
[27]. This type of epigenetic regulation is possible and 
may account for the global regulation of T-UCRS observed 
here. Also of note is that predominately intragenic rather 
than intergenic T-UCRs were increased in the mouse 
Figure 5: T-UCR expression in EGR1 knockout PANC-1 cells. A. EGR1 expression in normal pancreas and PDAC from data 
set GSE71989. B. Differential expression of transcription factors in patient specimens of normal pancreas and PDAC (GSE71989 data 
set) ranked as -log(p)×FC. C. The CRISPR/Cas9 system was used to knockout the EGR1 gene in PANC-1 pancreatic cancer cells. The 
immunoblot of EGR1 and beta actin are shown in EGR1 knockout (KO) and wildtype (WT) PANC-1 cells. D. Expression values of T-UCRs 
in the EGR1 KO compared to WT cells were converted to Log2 (fold change) and the Log2 (fold change) are compared to p-values using a 
Volcano plot. Dots represent the mean of triplicate biological replicates for a given T-UCR. A threshold of P < 0.05 and fold change greater 
than 1.5-fold (red symbols) was applied to determine statistical significance, **** P < 0.0001.
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and human data sets (Figure 1E, 1F). This finding may 
offer clues as to the general regulation of intragenic and 
intergenic T-UCRs in PDAC.
Three T-UCRs were increased in the patient 
samples, during experimental desmoplasia, a mouse model 
of PDAC and pancreatic cancer cell lines (Figure 2A). All 
three increased UCRs, UC.190, UC.233 and UC.270, are 
intronic according to the Mestdagh, et al., annotation [27]. 
UC.190 is found within the FOXP4 gene, UC.233 within 
the AGAP3 gene and UC.270 is located in the MAPKAP1 
gene. Examination of the gene expression profiling data 
(GSE71989) showed that the expression of these three 
T-UCR host genes did not increase in the PDAC compared 
to normal pancreas (data not shown). The genes encoding 
UC.190, UC.233 and UC.270 are on the same strand as 
the host genes. Since the expression of the host gene did 
not correlate with the T-UCR, it suggests that these three 
T-UCRs exists as transcripts that are separate from the 
T-UCR host gene pre-mRNA. Knockdown of the three 
T-UCRs using siRNA or gapmers reduced the proliferation 
of MIA PaCa-2 and PANC-1 cells as well as the host gene 
expression (Figure 3 and Supplementary Figure S3). 
Since both T-UCR and host gene mRNA were reduced by 
gene knockdown, we cannot rule out the possibility that 
knockdown of the host gene mRNA did not contribute to 
the reduction in cell proliferation.
We present here the first profiling study of T-UCRs 
in PDAC and identify a universal increase in this class 
of non-coding RNAs during disease progression in both 
human and mice. We further isolate three T-UCRs that 
are increased in multiple models of PDAC and lead 
to decreased cell viability when inhibited implicating 
UC.190, UC.233 and UC.270 as possible regulators of 
PDAC oncogenesis. These findings implicate T-UCRs as 
potential biomarkers or therapeutic targets for PDAC.
MATERIALS AND METHODS
Cells lines
The PDAC cells lines MIA PaCa-2, PANC-1, 
PL45 and SW1990 were obtained from the American 
Type Culture Collection (Manassas, VA). MIA PaCa-2, 
PL45 and PANC-1 cells were cultured using standard 
conditions with Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum (FBS) (Life 
Technologies, Grand Island, NY). SW1990 cells were 
cultured using Leibovitz’s L-15 media supplemented 
with 10% FBS. The normal pancreatic ductal cell line 
HPDE was obtained from Dr. Ming-Sound Tsao, Ontario 
Cancer Institute, Toronto, Ontario. HPDE cells were 
cultured in keratinocyte medium containing 30 µg/ml of 
bovine pituitary extract and 0.2 ng/ml of human rEGF 
(Life Technologies, Grand Island NY). HPNE cells were 
a generous gift of Dr. Michel Ouellette, University of 
Nebraska and were cultured in Medium D as previously 
described [35]. All cells lines were successfully 
authenticated by Genetica DNA Laboratories, (Cincinnati, 
OH) or by the Interdisciplinary Center for Biotechnology 
Research, University of Florida (Gainesville, FL). Data are 
presented in Supplementary Table S6. Duplicate biological 
replicates of all cell lines were profiled.
Tumor procurement
Pancreatic tissue samples were derived from 
patients undergoing a surgical procedure to remove a 
portion of the pancreas at the University of Oklahoma 
Health Sciences Center. Sample collection conformed to 
the policies and practices of the facility’s Institutional 
Review Board. Sections from each specimen were 
examined by a pathologist to confirm that they were 
PDAC or unaffected benign tissue and were flash frozen 
in liquid nitrogen within 15 minutes of surgery. Samples 
denoted as normal pancreas were derived from subjects 
that expired from causes other than pancreatic disease 
and were purchased from various suppliers. Total 
RNA was extracted from the frozen tissues following 
pulverization in a cold mortar and pestle and total RNA 
was isolated using Trizol reagent (Invitrogen). The RNA 
integrity number (RIN) was determined using the Agilent 
2100 Bioanalyzer. Patient demographics are listed in 
Supplementary Table S7.
Transgenic mice
Transgenic mice harboring an activating Kras mutation 
were used. Total RNA fromPdx-1-Cre;KrasLSL-G12D/wt, 
P48Cre/wt; KrasLSL-G12D/wt and control mice was isolated using 
miRNeasy (Qiagen) according to the manufacturer’s protocol 
and the RIN was determined using the Agilent Bioanalyzer. 
KrasG12D shows a consistent pancreatic expression under the 
P48 promoter, but shows a stochastic pattern of expression 
under the Pdx-1 promoter. In the Pdx-1-Cre;KrasLSL-G12D/wt 
mice low grade PanIN precursor lesions may arise as early as 
two weeks of age with PanIN-2 and PanIN-3 evident at 7-10 
months [36]. The median age of the mice was 209 days (Pdx-
1-Cre;KrasLSL-G12D/wt) and 34 (young) and 239 (old) days for 
P48Cre/wt; KrasLSL-G12D/wt. The median age of the control mice 
was 52 days. Detailed information on the mice may be found 
in Supplementary Table S8.
qPCR
Total RNA was isolated from the cells or tissues 
using the Trizol protocol. RNA was treated with DNase 
I and cDNA was made from the RNA using SuperScript 
II reverse transcriptase (Invitrogen Carlsbad, CA) and 
random primers. Since we used random primers for the 
reverse transcription step, we are unable to determine 
the directionality of the transcription (i.e. plus or minus 
strand) from the profiling experiments. The expression 
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of 481 T-UCRs was profiled in the cDNA using primers 
designed to each of the 481 T-UCRs. Primers were 
designed to hybridize to the sequence of the T-UCR 
genes as delineated by Berjano, et al., [15]. All primer 
sequences are included in Supplementary Table S9. 
qPCR was performed on an Applied Biosystems 7900 
HT real-time PCR instrument that was equipped with a 
384-well reaction plate using standard conditions. 18S 
rRNA or U6 snoRNA was used as the reference gene and 
data were analyzed using the comparative CT method. 
To validate the normalizer for the qPCR, we report the 
CT values for the various test and control groups for all 
experiments performed in the study. The data reported 
in Supplementary Figure S5 and Supplementary Table 
S10  demonstrates that the expression of the internal 
control gene was not significantly changed between the 
test and control groups (FC < 1.5, P > 0.05). A T-UCR 
was considered expressed in a particular sample if the 
mean CT ≤ 36 and they were considered differentially 
expressed if the fold change between the comparative 
groups was greater than 1.5-fold and P < 0.05 (Student’s 
t-test). To determine if the plus or minus strand was 
transcribed, strand specific qPCR was applied using 
sense or antisense RT primers as previously described 
[17].
Gene expression profiling
The gene expression of 14 PDAC and 8 normal 
pancreas specimen RNAs was profiled on Affymetrix 
HG-U133 Plus 2 microarrays at the gene expression core 
lab at the Ohio State University Comprehensive Cancer 
Center. Gene expression raw data from Affymetric 
microarrays were processed and normalized using 
‘affy’ R package from Bioconductor [37]. Data were 
normalized using the RMA algorithm [38], t-test was 
performed using R’s built-in default statistical package. 
False discovery rate was controlled by utilizing q 
statistics using ‘qvalue’ R package from bioconductor. 
Gene expression data are presented in the GEO data set 
using the identifier GSE71989.
Matrix deposit assay
Matrix deposit procedures were adapted from 
Ottaviano, et al [26]. HPDE cells were cultured on a matrix 
deposited by PANC-1 cell lines. To deposit the matrix, cell 
lines were plated at 105 cells/well and cultured in 6-well 
plates for 72 hours. Cells were removed by treatment 
with 20 mM ammonium hydroxide for 5 minutes. After 
incubation, the wells were washed 3 times with sterile PBS. 
Removal of the cells was visually confirmed by microscopy. 
HPDE cells were cultured overnight in serum free medium 
and plated at 2x105 cells/well in supplement free media 
over the PANC-1 matrix or plastic control. HPDE cells 
were incubated between 24 hrs prior to isolation of RNA.
siRNA knockdown of T-UCRs
Transfections were performed in reverse with 
DharmaFECT 4 (Dharmacon). Briefly, DharmaFECT 
4 was mixed with Opti-MEM and added to the 24 well-
plate containing the siRNAs. The plate was incubated 
for 30 min on an orbital shaker to form a complex. 
Afterwards, 4,000 cells were added to each well. The final 
concentration of the siRNAs was 40 nM. At 72 h and 96 
h, cells were washed with PBS, lysed and counted with 
the Beckman Coulter Cell Counter. RNA was collected 
72 h after transfection and assayed by qPCR using U6 
snoRNA as the normalizer. Viability after transfection 
was measured by using the WST-1 assay according to the 
manufacturer’s protocol. All siRNA sequences used are 
included in Supplementary Table S11.
Gapmer knockdown of T-UCRs
PANC-1 and MIA PaCa-2 cells were plated in 
6 wells at a seeding density of 2 x 105 cells per well 
and left overnight to attach. The T-UCR gapmers were 
designed for individual T-UCR and ordered from 
Exiqon. Negative control A was used as the control 
for this study. The sequences for the 4 gapmers used 
are: Negative control A: 5’-AACACGTCTATACGC, 
UC.270: 5’-CCGCAGAGATAGAATT-3’, UC.233: 5’-GA 
GCGTGGAAAGCTAT-3’, UC.190: 5’-GTTAATTGCGG 
CCTTT-3’. T-UCR Gapmers were transfected at a 
concentration of 100 nM using Lipofectamine 3000. Forty-
eight h post-transfection, cells were briefly washed with 
PBS, lysed using Trizol and assayed by qRT-PCR using 
gene specific primer as described above. For the proliferation 
assay, PANC-1 and MIA-PaCa-2 cells were plated at 2,500 
cells per well in 96 well plates. The transfection concentration 
and procedure of transfection of the gapmers was similar to 
the knockdown experiment (100 nM). Cells were transfected 
and incubated for 96 h. Viability was measured using a 
WST1 assay.
EGR1 knockdown in PANC-1 cells
EGR1 sgRNA cloning was carried out using 
the CRISPR/Cas9 procedure as described [39]. Guide 
RNAs were designed using the online CRISPR 
design tool (http://crispr.mit.edu/). Forward primer 5’- 
CACCGCTGCAGATCTCTGACCCGTT-3’ and Reverse 
primer 5’- AAACAACGGGTCAGAGATCTGCAGC-3’ 
were cloned into the bicistronic expression vector px459 
which expresses both Cas9 mRNA and the sgRNA. PANC-
1 cells were plated in a 6 well plate at a seeding density of 
3 x 105 cells/well. Lipofectamine LTX was used to transfect 
the vector containing both Cas9 and the sgRNA. Forty-eight 
hours post transfection, the cells were re-plated into another 
6 well plate (1:5 dilution) and puromycin was introduced 
at a concentration of 1 µg/ml to the media to stably select 
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the cells with EGR1 sgRNA expression. Stable colonies 
obtained after 7 days of puromycin selection were collected 
and screened for EGR1 protein expression using western 
blotting technique. EGR1 and beta actin antibodies numbers 
4153 and 4970S, respectively, were used (Cell Signaling 
Technology, Danvers, MA).
Data analysis
Differential expression analysis was performed 
using unpaired Student’s t-test [40] with p-value threshold 
at 0.05 and additional criteria of fold change of at least 
1.5. For both types of samples, human pancreatic tissue 
samples as well as mouse pancreatic tissues the pairwise 
Pearson correlation coefficients were calculated for each 
pair of expressed T-UCRs in these specimens. Using all 
pairwise correlation coefficients the correlation matrix was 
calculated and used to generate heatmaps. Heatmaps were 
generated using Multi-Array Viewer software package 
[41] with tri-color gradient scheme where gradient of 
red represents positive correlation, white color represent 
zero correlation and blue gradient represents negative 
correlation. Unsupervised hieratical clustering [42] was 
performed on both of these correlation matrixes (human 
and mouse) to determine clusters of T-UCRs that have 
most similar pattern of correlation across the samples.
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